Reshma P. Shetty, who serves as a Director and as President & Founder of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), completed the sale of 26,271 shares of Class A common stock over two trading days, April 8 and April 9, 2026.
The disposal generated proceeds of $175,067. Share prices on the executed trades ranged from $6.397 to $6.93 per share. These dispositions were disclosed as connected to tax liabilities arising from the vesting of performance-based restricted stock units, or PSUs.
Related activity preceded the sales. On April 7 and April 8, Shetty exercised options that resulted in the acquisition of 55,476 shares of Class A common stock, with those exercises tied directly to the PSU vesting events.
Operational and financial context
Ginkgo reported its fourth-quarter 2025 results earlier, noting material progress in cash management and the impact of an operational restructuring. Management highlighted that, despite a revenue decline in the cell engineering segment, the company cut operating losses and lowered cash burn through aggressive cost reductions.
The company is also advancing its lab automation strategy. Ginkgo has introduced the Ginkgo Cloud Lab, a cloud-based platform that permits researchers to access its automated laboratory infrastructure remotely. The platform incorporates Reconfigurable Automation Carts, which are designed to improve modularity inside laboratory environments. Management has indicated a focus on expanding Autonomous Labs and plans to add more RAC cart automation systems at its Boston facility by the end of 2026.
On the coverage side, BTIG revised its price target for Ginkgo Bioworks to $5.00 from $9.00 and maintained a Sell rating. Analyst Mark A. Massaro issued the update following the company’s fourth-quarter conference call.
Market valuation note
While the stock has experienced recent weakness, analysis from InvestingPro cited in company commentary notes that Ginkgo may appear undervalued at current prices. The referenced InvestingPro service offers additional research and fair value tools for assessing DNA’s valuation and other U.S. equities.
This sequence of option exercises, tax-related share sales, corporate restructuring, and lab automation initiatives together reflect both compensation mechanics at the company and ongoing operational shifts intended to reduce cash burn and advance automation capabilities.